Nynomic (M7U) AGM 2026 presentation summary
Event summary combining transcript, slides, and related documents.
AGM 2026 presentation summary
13 Jul, 2026Group overview and strategic direction
Operates as a strategic financial holding with around 500 employees and a focus on optical metrology technologies.
Pursues a buy-and-build strategy, achieving average annual revenue growth of 10% and focusing on global photonics industry consolidation.
Comprises about 20 subsidiaries, with a strong presence in Europe, the USA, and Asia, and a particular focus on the US market.
Integrates a growing portfolio of brands dedicated to non-contact, non-destructive optical measurement.
Emphasizes vertical integration, offering solutions from components to complete systems.
Financial performance 2025 and Q1 2026
2025 revenue was €92.6 million, down 10% from the previous year, with EBIT dropping 73% to €2.0 million.
EBIT margin fell to 2% in 2025, but the cost efficiency program NyFIT2025 generated sustainable annual savings of over €5 million.
Q1 2026 saw revenue rise 8% year-over-year to €22.3 million, with EBIT turning positive at €0.1 million.
Order backlog increased 23% in Q1 2026, reflecting robust demand and a book-to-bill ratio above one.
Cash position at year-end 2025 was €14.5 million, with financial liabilities reduced by 37% to €3.1 million.
Market positioning and operational highlights
Participated in major industry events, expanded AI-based solutions, and strengthened capital market presence through investor conferences.
Enhanced efficiency through internal mergers and streamlined group structure, supporting operational performance.
Focuses on innovation in precision agriculture, medical lab automation, and semiconductor production control.
Leverages group synergies in sales, R&D, finance, marketing, IT, HR, and operations.
Technologies address high-growth markets such as smart farming, smart industry, and high-speed data communication.
Latest events from Nynomic
- Stable margins and growing order backlog offset lower sales, supporting a strong H2 outlook.M7U
H1 202413 Jul 2026 - Revenue and EBIT declined sharply, but strong order backlog and equity ratio support 2025 growth.M7U
H2 202413 Jul 2026 - Revenue down 12% and EBIT negative in H1 2025; outlook revised amid ongoing market challenges.M7U
H1 202513 Jul 2026 - Revenue and EBIT declined sharply, but restructuring sets up a return to growth in 2026.M7U
H2 202513 Jul 2026